Abstract:Background & aims: Macrophages contribute to liver disease, but their role in cholestatic liver injury, including primary sclerosing cholangitis (PSC), is unclear. We tested the hypothesis that macrophages contribute to the pathogenesis of, and are therapeutic targets for, PSC. Methods: Immune cell profile, hepatic macrophage number, localization and polarization, fibrosis, and serum markers of liver injury and cholestasis were measured in an acute (intrabiliary injection of the inhibitor of apoptosis antagonist BV6) and chronic (Mdr2-/- mice) mouse model of sclerosing cholangitis (SC). Selected observations were confirmed in liver specimens from patients with PSC. Because of the known role of the CCR2/CCL2 axis in monocyte/macrophage chemotaxis, therapeutic effects of the CCR2/5 antagonist cenicriviroc (CVC), or genetic deletion of CCR2 (Ccr2-/- mice) were determined in BV6-injected mice. Results: We found increased peribiliary pro-inflammatory (M1-like) and alternatively-activated (M2-like) monocyte-derived macrophages in PSC compared to normal livers. In both SC models, genetic profiling of liver immune cells identified a predominance of monocytes/macrophages; immunohistochemistry confirmed peribiliary monocyte-derived macrophage recruitment (M1>M2-polarized), which paralleled injury onset and was reversed upon resolution in acute SC mice. PSC, senescent and BV6-treated human cholangiocytes released monocyte chemoattractants (CCL2, IL-8) and macrophage-activating factors in vitro. Pharmacological inhibition of monocyte recruitment by CVC treatment or CCR2 genetic deletion attenuated macrophage accumulation, liver injury and fibrosis in acute SC. Conclusions: Peribiliary recruited macrophages are a feature of both PSC and acute and chronic murine SC models. Pharmacologic and genetic inhibition of peribiliary macrophage recruitment decreases liver injury and fibrosis in mouse SC. These observations suggest monocyte-derived macrophages contribute to the development of SC in mice and in PSC pathogenesis, and support their potential as a therapeutic target. Lay summary: Primary sclerosing cholangitis (PSC) is an inflammatory liver disease which often progresses to liver failure. The cause of the disease is unclear and therapeutic options are limited. Therefore, we explored the role of white blood cells termed macrophages in PSC given their frequent contribution to other human inflammatory diseases. Our results implicate macrophages in PSC and PSC-like diseases in mice. More importantly, we found that pharmacologic inhibition of macrophage recruitment to the liver reduces PSC-like liver injury in the mouse. These exciting observations highlight potential new strategies to treat PSC.

Macrophage polarization is involved in liver fibrosis induced by β<sub>1</sub>-adrenoceptor autoantibody

Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.

IL-17A produced by invariant natural killer T cells and CD3(+)CD56(+)alpha Galcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis

IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

Infiltration of Polarized Macrophages Associated with Liver Fibrosis in Infants with Biliary Atresia.

Macrophage Polarization and Its Role in Liver Disease

Mechanism of annexin A1/N-formylpeptide receptor regulation of macrophage function to inhibit hepatic stellate cell activation through Wnt/β-catenin pathway

Hepatic macrophages: Key players in the development and progression of liver fibrosis

β2-Adrenergic Receptor Enhances the Alternatively Activated Macrophages and Promotes Biliary Injuries Caused by Helminth Infection

Macrophage polarization in tissue fibrosis

Bone marrow‐derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells

The role of macrophage <scp>TAM</scp> receptor family in the acute‐to‐chronic progression of liver disease: from friend to foe?

Selective Targeting of α4β7/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver

ATG16L1 Depletion-Mediated Activation of the TRAF1 Signaling in Macrophages Aggravates Liver Fibrosis

Cannabinoid Receptor 1 Participates in Liver Inflammation by Promoting M1 Macrophage Polarization via RhoA/NF-κB p65 and ERK1/2 Pathways, Respectively, in Mouse Liver Fibrogenesis

Sphingosine kinase 1 aggravates liver fibrosis by mediating macrophage recruitment and polarization.

Polarization to Anti-Inflammatory Status of Macrophages Predicts Poor Prognosis of HBV-Related Acute-on-Chronic Liver Failure Patients Via Chloride Intercellular Channel 3 Suppression

The Proinflammatory Cytokines IL-18, IL-21, and IFN-γ Differentially Regulate Liver Inflammation and Anti-Mitochondrial Antibody Level in a Murine Model of Primary Biliary Cholangitis

The Role of Macrophage TAM Receptor Family in the Acute‐to‐chronic Progression of Liver Disease: from Friend to Foe?

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

Macrophage Subsets in the Development and Reversal of Liver Fibrosis

Macrophage polarization is involved in liver fibrosis induced by &beta;&lt;sub&gt;1&lt;/sub&gt;-adrenoceptor autoantibody